Genmab A/S (GNMSF) News Today → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free GNMSF Stock Alerts $284.45 +6.11 (+2.20%) (As of 05/9/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineGenmab A/S (OTCMKTS:GNMSF) Shares Pass Below Two Hundred Day Moving Average of $296.91americanbankingnews.com - May 9 at 6:26 AMBuy Rating Affirmed for Genmab on Strong TIVDAK Approval and Promising Pipeline Valuationmarkets.businessinsider.com - May 1 at 12:03 PMComstock Inc (LODE) Q1 2024 Earnings Call Transcript Highlights: Strategic Investments and ...finance.yahoo.com - May 1 at 7:03 AMGenmab A/S (OTCMKTS:GNMSF) Sees Large Growth in Short Interestamericanbankingnews.com - May 1 at 5:10 AMGenmab Acquires A Missing Piece For Its Pipelineseekingalpha.com - April 16 at 5:33 PMGenmab's Q1 Darzalex Sales By Johnson & Johnson Reach $2.692 Blnmarkets.businessinsider.com - April 16 at 7:32 AMTruist Financial Keeps Their Buy Rating on Genmab (GMAB)markets.businessinsider.com - April 9 at 5:33 PMProfoundBio discovers the joys of having a wealthy ownerbenzinga.com - April 8 at 1:36 PM30 Biggest Biotechnology Companies in the Worldfinance.yahoo.com - March 17 at 8:59 AMPassing of Genmab A/S’ Annual General Meetingfinance.yahoo.com - March 13 at 12:58 PMGenmab: Recent Updates Support The Growth Narrativeseekingalpha.com - February 21 at 5:40 AM4 Analysts Assess Genmab: What You Need To Knowmarkets.businessinsider.com - February 20 at 1:00 PMGenmab A/S’ New Regulation Risk – A Cause for Worry?msn.com - February 15 at 12:38 PMGenmab A/S (NASDAQ:GMAB) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 15 at 12:38 PMNotice to Convene the Annual General Meeting of Genmab A/Sfinance.yahoo.com - February 15 at 7:38 AMGenmab Files Annual Report with the U.S. Securities and Exchange Commissionfinance.yahoo.com - February 14 at 4:15 PMGenmab: Growth Is Still a Better Choicefinance.yahoo.com - February 14 at 4:15 PMTisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancerfinance.yahoo.com - February 2 at 7:26 AMCracking The Code: Understanding Analyst Reviews For Genmabmarkets.businessinsider.com - January 29 at 8:44 AMGrant of Restricted Stock Units and Warrants to Employees in Genmabfinance.yahoo.com - January 25 at 5:23 PMGenmab Announces Decision in Arbitration Appeal under License Agreement with Janssenfinance.yahoo.com - January 22 at 7:38 PMHRMY or GMAB: Which Is the Better Value Stock Right Now?finance.yahoo.com - December 7 at 2:14 PMGenmab A/S (NASDAQ:GMAB) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 8 at 7:38 PMGenmab reports 9M resultsmsn.com - November 7 at 6:13 PMGenmab Announces Financial Results for the First Nine Months of 2023finance.yahoo.com - November 7 at 1:13 PMGenmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)finance.yahoo.com - November 2 at 10:08 AMGenmab and Seagen report positive data from Phase III TIVDAK trialmsn.com - October 23 at 11:23 PMSeagen, Genmab update Phase 3 data for uterine cancer therapymsn.com - October 23 at 6:22 PMGenmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023finance.yahoo.com - October 17 at 6:28 AMWhat 13 Analyst Ratings Have To Say About Genmabbenzinga.com - October 13 at 1:47 PMDiversified Stock Portfolio: 10 Sector ETFs and International ETFs to Buyfinance.yahoo.com - September 28 at 1:23 PMEPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)finance.yahoo.com - September 25 at 9:13 AMEPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)finance.yahoo.com - September 25 at 9:13 AMGenmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)finance.yahoo.com - September 25 at 9:13 AMGenmab : Phase 3 Trial Of TIVDAK In Recurrent Or Metastatic Cervical Cancer Meets Primary Endpointmarkets.businessinsider.com - September 4 at 9:52 PMSeagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alonefinance.yahoo.com - September 4 at 4:52 PMGenmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapyfinance.yahoo.com - September 4 at 4:52 PMUPDATE 1-Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpointfinance.yahoo.com - September 4 at 4:52 PMGenmab to Present at Morgan Stanley 21st Annual Global Healthcare Conferencefinance.yahoo.com - August 28 at 2:26 PMGenmab Announces Financial Results for the First Half of 2023finance.yahoo.com - August 3 at 3:39 PMGenmab Updates 2023 Financial Guidancefinance.yahoo.com - July 28 at 1:14 AMCould This New Drug Be a Blockbuster for These 2 Pharma Collaborators?finance.yahoo.com - July 2 at 9:55 AMGenmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)finance.yahoo.com - June 27 at 7:35 PMGenmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’finance.yahoo.com - June 22 at 7:28 AMGenmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023finance.yahoo.com - June 9 at 4:17 AMExpert Ratings for Genmabbenzinga.com - June 6 at 2:30 PMGenmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conferencefinance.yahoo.com - June 6 at 4:28 AMEPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)finance.yahoo.com - May 19 at 2:46 PMUPDATE 2-US FDA approves Genmab-AbbVie's blood cancer therapyfinance.yahoo.com - May 19 at 2:46 PMGenmab Announces Financial Results for the First Quarter of 2023finance.yahoo.com - May 10 at 11:04 AM Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter. Email Address The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet. See how you can invest alongside him GNMSF Media Mentions By Week GNMSF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNMSF News Sentiment▼-1.160.43▲Average Medical News Sentiment GNMSF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNMSF Articles This Week▼20▲GNMSF Articles Average Week Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Bayer Aktiengesellschaft News Today Context Therapeutics News Today EOM Pharmaceuticals News Today Hypera News Today IMV News Today International Stem Cell News Today LAVA Therapeutics News Today Mainz Biomed News Today NLS Pharmaceutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:GNMSF) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaObama’s Forever Term [exposed]Porter & CompanyThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders348 million Americans lives to END as we know it?The Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
